Elevation Oncology Results, Recent Business Achievements

 Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan; expect to announce initial safety and efficacy data by mid-3Q 2024, with additional data in 1H 2025 --

-- Presented preclinical proof-of-concept data for HER3-ADC program at AACR Annual Meeting; on-track to nominate development candidate in 2H 2024 --

-- Raised $44.2 million year-to-date through ATM facility, extending cash runway into 2026 --

https://www.biospace.com/article/releases/elevation-oncology-reports-first-quarter-2024-financial-results-and-highlights-recent-business-achievements/